Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR2 | O15552 | 9/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | PRCP | P42785 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 3/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | GRN | P28799 | 1/20 | 0.38 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1906571 | 1.00 | FFAR2 (0.47) | FFAR2POLBPRCPBRD4PPARG | |
| SCHEMBL22491784 | 1.00 | FFAR2 (0.47) | FFAR2POLBPRCPBRD4PPARG | |
| SCHEMBL1905489 | 1.00 | FFAR2 (0.47) | FFAR2POLBPRCPBRD4PPARG | |
| Benzoquinone SCHEMBL22491815 | 0.92 | FFAR2 (0.42) | FFAR2POLBPRCPBRD4PPARG | |
| SCHEMBL14798252 | 0.89 | CYP2D6 (0.46) | FFAR2POLBCYP2D6 | |
| SCHEMBL1932498 | 0.89 | CYP2D6 (0.46) | FFAR2POLBCYP2D6 | |
| SCHEMBL1907199 | 0.86 | FFAR2 (0.47) | FFAR2PRCPBRD4ADRB2 | |
| SCHEMBL1905993 | 0.86 | FFAR2 (0.47) | FFAR2PRCPBRD4ADRB2 | |
| SCHEMBL24893814 | 0.86 | AKR1C3 (0.46) | PPARGGRNSORT1 | |
| SCHEMBL24893827 | 0.86 | AKR1C3 (0.46) | PPARGGRNSORT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220234996-A1 | Method for Producing (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclo-propylpropanoic Acid and the Crystalline Form Thereof for Use as a Pharmaceutical Ingredient | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-07-28 | — | — | US | disclosed |
| US-11332435-B2 | Method for producing (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4- chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclo-propylpropanoic acid and the crystalline form thereof for use as a pharmaceutical ingredient | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-05-17 | — | — | US | disclosed |
| US-11332435-B2 | Method for producing (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4- chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclo-propylpropanoic acid and the crystalline form thereof for use as a pharmaceutical ingredient | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-05-17 | — | — | US | disclosed |
| US-20210179541-A1 | Method for Producing (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclo-propylpropanoic Acid and the Crystalline Form Thereof for Use as a Pharmaceutical Ingredient | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-06-17 | — | — | US | disclosed |
| US-20210179541-A1 | Method for Producing (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclo-propylpropanoic Acid and the Crystalline Form Thereof for Use as a Pharmaceutical Ingredient | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-06-17 | — | — | US | disclosed |
| EP-3717480-A1 | METHOD FOR PRODUCING (3S)-3-(4-CHLOR-3-{[(2S,3R)-2-(4-CHLORPHENYL)-4,4,4-TRIFLUOR-3-METHYLBUTANOYL]AMINO}PHENYL)-3-CYCLO-PROPYLPROPANOIC ACID AND THE CRYSTALLINE FORM THEREOF FOR USE AS A PHARMACEUTICAL INGREDIENT | Bayer Pharma Aktiengesellschaft (DE) | 2020-10-07 | — | — | EP | disclosed |
| CN-111433204-A | Process for the preparation of (3S) -3- (4-chloro-3- { [ (2S,3R) -2- (4-chlorophenyl) -4,4, 4-trifluoro-3-methylbutyryl ] amino } phenyl) -3-cyclopropylpropionic acid and crystalline forms thereof for use as a pharmaceutically active substance | 拜耳制药股份公司 | 2020-07-17 | — | — | CN | disclosed |
| US-10023528-B2 | Branched 3-phenylpropionic acid derivatives and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-07-17 | — | — | US | disclosed |
| EP-2570460-B1 | Dual color electronically addressable ink | HEWLETT PACKARD DEVELOPMENT CO LP (US) | 2017-06-14 | — | — | EP | disclosed |
| US-20160264515-A1 | Branched 3-phenylpropionic acid derivatives and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-09-15 | — | — | US | disclosed |
| US-20130079412-A1 | Branched 3-phenylpropionic acid derivatives and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-03-28 | — | — | US | disclosed |
| US-20130071690-A1 | DUAL COLOR ELECTRONICALLY ADDRESSABLE INK | HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. | 2013-03-21 | — | — | US | disclosed |
| EP-2570460-A2 | Dual Color Electronically Addressable Ink | Hewlett-Packard Development Company, L.P. (US) | 2013-03-20 | — | — | EP | disclosed |
| US-20120172448-A1 | Substituted 1-benzylcycloalkylcarboxylic acids and the use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-07-05 | — | — | US | disclosed |
| US-20120172448-A1 | Substituted 1-benzylcycloalkylcarboxylic acids and the use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-07-05 | — | — | US | disclosed |
| US-20120172448-A1 | Substituted 1-benzylcycloalkylcarboxylic acids and the use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-07-05 | — | — | US | disclosed |
| WO-2012076466-A2 | SUBSTITUTED 1-BENZYLCYCLOALKYLCARBOXLIC ACIDS AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-06-14 | — | — | WO | disclosed |
| EP-0218368-B1 | IMPROVEMENTS RELATING TO PESTICIDES | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1990-06-13 | — | — | EP | disclosed |
| US-4874781-A | INSECTICIDES | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1989-10-17 | — | — | US | disclosed |
| EP-0218368-A1 | Improvements relating to pesticides | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1987-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220234996-A1 | Method for Producing (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclo-propylpropanoic Acid and the Crystalline Form Thereof for Use as a Pharmaceutical Ingredient | FABP3, PCCA, HMGCR | FFAR2 75/4885POLB 4083/4885PRCP 80/4885 |
| US-20160264515-A1 | Branched 3-phenylpropionic acid derivatives and their use | PC, FABP3, PCCA | FFAR2 169/4885POLB 1933/4885PRCP 522/4885 |
| US-20130079412-A1 | Branched 3-phenylpropionic acid derivatives and their use | PC, FABP3, PCCA | FFAR2 169/4885POLB 1933/4885PRCP 522/4885 |
| US-20210179541-A1 | Method for Producing (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclo-propylpropanoic Acid and the Crystalline Form Thereof for Use as a Pharmaceutical Ingredient | FABP3, PCCA, HMGCR | FFAR2 75/4885POLB 4083/4885PRCP 80/4885 |
| US-10023528-B2 | Branched 3-phenylpropionic acid derivatives and their use | PC, FABP3, PCCA | FFAR2 169/4885POLB 1933/4885PRCP 522/4885 |
| US-20120172448-A1 | Substituted 1-benzylcycloalkylcarboxylic acids and the use thereof | PC, ACACA, PCCA | FFAR2 154/4885POLB 3613/4885PRCP 878/4885 |
| US-11332435-B2 | Method for producing (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4- chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclo-propylpropanoic acid and the crystalline form thereof for use as a pharmaceutical ingredient | FABP3, PCCA, HMGCR | FFAR2 75/4885POLB 4083/4885PRCP 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.